181 related articles for article (PubMed ID: 30009703)
21. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
22. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors.
Marzaro G; Chilin A; Guiotto A; Uriarte E; Brun P; Castagliuolo I; Tonus F; González-Díaz H
Eur J Med Chem; 2011 Jun; 46(6):2185-92. PubMed ID: 21447431
[TBL] [Abstract][Full Text] [Related]
23. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
24. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
Hur W; Velentza A; Kim S; Flatauer L; Jiang X; Valente D; Mason DE; Suzuki M; Larson B; Zhang J; Zagorska A; Didonato M; Nagle A; Warmuth M; Balk SP; Peters EC; Gray NS
Bioorg Med Chem Lett; 2008 Nov; 18(22):5916-9. PubMed ID: 18667312
[TBL] [Abstract][Full Text] [Related]
25. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
[TBL] [Abstract][Full Text] [Related]
26. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
27. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
[No Abstract] [Full Text] [Related]
28. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
29. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion.
Carmi C; Lodola A; Rivara S; Vacondio F; Cavazzoni A; Alfieri RR; Ardizzoni A; Petronini PG; Mor M
Mini Rev Med Chem; 2011 Oct; 11(12):1019-30. PubMed ID: 21861809
[TBL] [Abstract][Full Text] [Related]
31. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
[TBL] [Abstract][Full Text] [Related]
32. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
Shao J; Markowitz JS; Bei D; An G
J Pharm Sci; 2014 Dec; 103(12):3810-3833. PubMed ID: 25308414
[TBL] [Abstract][Full Text] [Related]
33. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
34. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.
Lanning BR; Whitby LR; Dix MM; Douhan J; Gilbert AM; Hett EC; Johnson TO; Joslyn C; Kath JC; Niessen S; Roberts LR; Schnute ME; Wang C; Hulce JJ; Wei B; Whiteley LO; Hayward MM; Cravatt BF
Nat Chem Biol; 2014 Sep; 10(9):760-767. PubMed ID: 25038787
[TBL] [Abstract][Full Text] [Related]
35. Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.
Liu B; Huang X; Hu Y; Chen T; Peng B; Gao N; Jin Z; Jia T; Zhang N; Wang Z; Jin G
Oncotarget; 2016 Sep; 7(36):58038-58050. PubMed ID: 27487128
[TBL] [Abstract][Full Text] [Related]
36. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
Wang XK; Fu LW
Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
[TBL] [Abstract][Full Text] [Related]
37. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
38. Reactive Chemical Probes: Beyond the Kinase Cysteinome.
Jones LH
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9220-9223. PubMed ID: 29644769
[TBL] [Abstract][Full Text] [Related]
39. An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
Chaikuad A; Diharce J; Schröder M; Foucourt A; Leblond B; Casagrande AS; Désiré L; Bonnet P; Knapp S; Besson T
J Med Chem; 2016 Nov; 59(22):10315-10321. PubMed ID: 27766861
[TBL] [Abstract][Full Text] [Related]
40. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
